SHAREHOLDER ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Neurotrope, Inc.

LOS ANGELES--()--Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq: NTRP) for violations of §10(b) and §20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder.

Investors who purchased the Company’s shares between January 7, 2016 and April 28, 2017 inclusive (the “Class Period”), are encouraged to contact the firm before July 17, 2017, the lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate.

We also encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.goldberglawpc.com/, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that during the Class Period, Neurotrope made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about the efficacy of its lead product candidate, Bryostatin-1, in clinical trials. On May 1, 2017, the Company announced “positive top-line results” for the focal Phase 2b trials of Bryostatin-1, mentioning “improvement in patients with moderate to severe Alzheimer's disease.” The trial data negated these statements, however, as the top-line data relating to the 20-microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40-microgram dose in connection with its primary and secondary endpoints. Following this news, Neurotrope’s stock price fell materially, which caused investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
info@goldberglawpc.com
www.Goldberglawpc.com

Contacts

Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401
info@goldberglawpc.com
www.Goldberglawpc.com